Increasing Investment in Research is Propelling the Growth of the Bulk Drug Market in the APAC Region!

The Asia Pacific bulk drug market is a significant contributor to the global bulk drug market, which is expected to grow significantly in the coming years. The Asia Pacific region is home to some of the world’s most populous countries, such as China and India, which present a vast market for Bulk drug-based medications. The increasing prevalence of chronic diseases such as cardiovascular diseases, which require the use of bulk drug-based medications is among the important reasons for the market growth of the bulk drug market in the region. For instance, as per the Australian Institute of Health and Welfare, from 2020 to 2021, Cardiac Heart Disease was the predominant diagnosis in approximately 160,000 hospitalizations.

Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=43755

Further, the Asia-Pacific Bulk Drug Market is expected to grow at a strong CAGR of 12% during the forecast period (2022-2030). The increasing demand for generic drugs in the region is due to the increasing patent expiration of the branded drugs.

APAC Bulk Drug Market Revenue (2020-2030)- USD Mn

Based on type, the market is segmented into antibiotics, sulpha drugs, vitamins, steroids, analgesics, and others. As per our analysis, the antibiotics segment acquired a major share in 2021. The bulk drug market for antibiotics is also influenced by factors such as regulatory policies, patent expirations, and the emergence of antibiotic-resistant bacteria. The emergence of antibiotic-resistant bacteria is the major driving factor for the development of new antibiotics.

Based on the type, the market is segmented into oral and intravenous. As per our analysis, the oral segment held the dominant share in 2021. Oral medicines are preferable for patients as they are easy to consume and chemically as well as biologically more stable. Further, these drugs are cost-efficient as these drugs don’t undergo sterilization procedures which is also an important factor for the large share of the segment.

Based on end-user, the market is segmented into hospitals, clinics, home care settings, and ambulatory surgical centers. As per our analysis, the home care settings segment is expected to grow at a higher CAGR during the forecast period. In homecare settings, Bulk may be prescribed for patients who are unable to visit a medical facility regularly or have mobility issues. Homecare providers can monitor the patient’s vital signs and adjust the dosage as needed. Additionally, homecare settings can be more convenient and cost-effective for patients who require long-term treatment with Bulk.

For a detailed analysis of Global Bulk Drug Market browse through – https://univdatos.com/report/bulk-drug-market/

Global Bulk Drug Market Segmentation

Market Insight, by Type

• Antibiotics
• Sulpha Drugs
• Vitamins
• Steroids
• Analgesics
• Others

Market Insight, by End-Use

• Pharmaceuticals
• Biotechnology
• Veterinary Medicine

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • India
  • Rest of APAC
• Rest of the World

Top Company Profiles

• Dr. Reddy’s Laboratories Ltd.
• Merck & Co., Inc• Bayer AG• Merck KGaA• Cambrex Corporation• Teva Pharmaceutical Industries Ltd.• Johnson & Johnson Private Limited.• BASF SE• Novartis AG• Pfizer Inc